Skip to main content
PsyBio Therapeutics Corp. logo

PsyBio Therapeutics Corp. — Investor Relations & Filings

Ticker · PSYBF ISIN · CA74464R1000 LEI · 549300KO32JSWBZIZP18 TSXV Manufacturing
Open in API
Filings indexed 119 across all filing types
Latest filing 2022-06-02 Regulatory Filings
Country CA Canada
Listing TSXV PSYBF

About PsyBio Therapeutics Corp.

www.psybiolife.com

PsyBio Therapeutics Corp. is an intellectual property-driven biotechnology company focused on the discovery, design, and development of psycho-targeted therapeutics for mental and neurological conditions, including CNS disorders. The company develops a portfolio of novel psychoactive compounds and their analogues. A key differentiator is its proprietary platform utilizing genetically modified bacteria for the scalable, biosynthetic manufacturing of psychoactive molecules, such as tryptamines. PsyBio is actively engaged in preclinical studies and developing its own compounds, aiming to improve treatments for various psychologic and neurologic conditions.

Recent filings

Filing Released Lang Actions
News release - English.pdf
Regulatory Filings Classification · 95% confidence The document is a press release announcing that PsyBio Therapeutics has initiated commercial biosynthetic process development for psychoactive compounds, focusing on manufacturing technology and progress towards GMP production. It discusses the company's development milestones, manufacturing process, and future plans related to clinical trials and regulatory filings. There are no financial statements, earnings data, or detailed financial analysis present. The document is not a report but rather a corporate announcement about operational progress and development milestones. It does not fit into categories like Annual Report, Interim Report, Earnings Release, or Regulatory Filings related to financial or governance disclosures. It is a general corporate update press release about process development and manufacturing progress, which aligns best with the Regulatory Filings (RNS) category as a general announcement that does not fit other specific categories.
2022-06-02 English
Notice of the meeting and record date (amended) - English.pdf
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a notice regarding the upcoming Annual and Special Meeting of Psybio Therapeutics Corp., including details such as meeting date, record date, and securities entitled to vote. It does not contain the actual meeting materials, voting results, or financial data. The document is short (1179 characters) and serves as an announcement of meeting details rather than the meeting materials themselves. Therefore, it fits the category of a Proxy Solicitation & Information Statement (PSI) or possibly a Regulatory Filing (RNS). However, since it specifically provides notice of meeting and record date information related to shareholder voting, it aligns best with Proxy Solicitation & Information Statement (PSI).
2022-05-19 English
News release - English.pdf
Regulatory Filings Classification · 95% confidence The document is a press release announcing a development in the commercial purification process for a pharmaceutical compound by PsyBio Therapeutics. It discusses manufacturing process achievements, potential impacts on clinical trials, and regulatory filings such as IND applications with the FDA. There are no financial statements, earnings data, or detailed financial analysis present. The document is not a report but rather a corporate announcement about operational progress and future plans. It does not fit into categories like Annual Report, Interim Report, Earnings Release, or Regulatory Filings related to financial compliance. It is best classified as a general regulatory announcement or corporate update that does not fit other specific categories, thus falling under Regulatory Filings (RNS). The document length and content support this classification with high confidence.
2022-05-16 English
Notice of the meeting and record date (amended) - English.pdf
AGM Information Classification · 95% confidence The document is a notice regarding the upcoming Annual and Special Meeting of securityholders, including details such as meeting date, record date, and voting information. It does not contain the actual meeting materials or results, nor does it include financial statements or detailed reports. The document is short (1172 characters) and serves as an announcement of meeting logistics rather than the meeting content or results. Therefore, it fits the category of AGM Information (AGM-R), which covers presentations and materials shared during the Annual General Meeting or notices related to it.
2022-05-13 English
News release - English.pdf
Regulatory Filings Classification · 95% confidence The document is a press release announcing the initiation of blood-brain barrier permeability testing for PsyBio Therapeutics' pipeline compounds. It discusses the company's research and development activities, future plans, and forward-looking statements. There are no financial statements, regulatory filings, voting results, or management changes reported. The content is primarily an operational update and business development announcement rather than a formal financial or regulatory report. It does not fit into categories like Annual Report, Interim Report, Earnings Release, or Regulatory Filings. It is also not a presentation or call transcript. Given the nature of the content as a corporate news release about research progress and pipeline development, the best fitting category is Regulatory Filings (RNS), which serves as a fallback for miscellaneous announcements that do not fit other specific categories.
2022-05-06 English
News release - English.pdf
Regulatory Filings Classification · 95% confidence The document is a press release announcing that PsyBio Therapeutics has begun filing global provisional patent conversion applications to strengthen its biosynthetic patent portfolio. It discusses intellectual property protection, patent filings, and the company's development focus. There is no mention of financial data, regulatory filings, management changes, earnings, or other report types. The content is primarily a corporate announcement about patent activity and intellectual property strategy. This fits best under the category of a general regulatory or corporate announcement that does not fit into more specific financial or governance categories. Therefore, the most appropriate classification is Regulatory Filings (RNS). The document length is 9133 characters, which is substantial but the content is not a financial report or detailed management discussion, nor is it an announcement of a report publication. Hence, RNS is the best fit with high confidence.
2022-04-27 English

Browse filings by year

4 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.